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Among the 75 subjects enrolled in this study, we detected 43 wild types, 22 heterozygotes, and 10 C282Y homozygotes. All of the latter group belonged to HH families (five probands and four relatives) other than one with a histological diagnosis related to hemochromatosis.
Deviations of 2°C from the selected hybridization temperature produced cross-hybridization between mismatched probes and target DNAs. The cutoff value, calculated in each experiment as the mean absorbance of two negative controls plus 3 SD, was 0.110 Ϯ 0.04 (mean Ϯ SD; range, 0.097-0.124). Under these conditions, we could always discriminate between positive and negative reactions. In all experiments at the selected cutoffs, we found no false-positive results, and the absorbance at 450 nm was 1.290 -2.560 after specific hybridization with both probes. The signal generated by the heterozygous DNA with the two specific probes was roughly one-half the signal generated by the homozygous DNA hybridized with the complementary probe ( Table 1) . We assessed the specificity of the method by adding unrelated PCR products of noncomplementary sequences (HLA and ␤-globin) to microtiter plates containing HH probes; the signals obtained were indistinguishable from background. Moreover, the results obtained with DEIA completely matched the results obtained with restriction enzyme analysis genotyping both in terms of specificity and sensitivity.
Recently, Jeffrey et al. (6 ) reported that use of the original primers described by Feder et al. (3 ) in samples with the 5569G/A polymorphism may lead to misidentification of C282Y heterozygotes as homozygotes. To avoid erroneous genotyping and overestimation of homozygotes, Jeffrey et al. (6 ) developed a new antisense primer that excluded the site of the new polymorphism. These alternative primers can be substituted directly into our method because they give a PCR product almost identical to the one obtained with the primers used by Feder et al. (3 ) , other than the 5569G/A site, and do not influence the binding regions of the specific probes that we used in the DEIA.
In conclusion, we have developed a nonisotopic hybridization system for the detection of the C282Y mutation in HFE gene sequences amplified by PCR. The method provides definitive data and is highly specific and sensitive. In addition, the procedure is simpler, faster, and less expensive than electrophoresis-based mutation analyses as well as other ELISA-coupled assays, such as oligonucleotide ligation assays, that require the use of fluorochrome-labeled probes. In the DEIA assay, the use of an anti-double-stranded DNA monoclonal antibody directly identifies the hybridization event itself and therefore bypasses the difficulty of DNA modification. The reagents and general assay scheme are well suited for routine analysis. Moreover, the use of 96-well microtiter plates allows simultaneous testing of several samples, greatly facilitating the large-scale screening of inherited diseases. The gold standard for the evaluation of the glomerular filtration rate (GFR) is inulin clearance (CIn), but its widespread use is prevented by several technical difficulties (1 ). The most commonly used marker for GFR is serum creatinine. However, serum creatinine concentrations should be interpreted with caution as a filtration marker in liver cirrhosis because they do not adequately reflect renal dysfunction. Increased tubular secretion and muscle wasting account for the disparity between creatinine concentrations and GFR in cirrhotic patients (2) (3) (4) . Thus, GFR has been demonstrated repeatedly to be overestimated by serum creatinine (1) (2) (3) (4) (5) .
Cystatin C, a cationic 13-kDa protein that is produced by nucleated cells and catabolized by the renal tubular cells after passing the glomerular filter, has recently been reported as a reliable endogenous marker of GFR in healthy adults and children as well as in patients with nephrologic, urologic, and rheumatologic disorders (6 -9 ) . For patients with liver cirrhosis, however, no data are available. Therefore, we studied cystatin C in comparison to creatinine for the assessment of GFR in these patients. We also determined the precision (10 ) of each analyte to predict GFR in cirrhotic patients.
Forty-four patients with liver cirrhosis who were clas- Table 1 ). The causes of liver disease were alcoholism (n ϭ 31), viral hepatitis (n ϭ 10), and other liver diseases (n ϭ 3). No patient had evidence of renal disease as assessed by examination of urinary sediment and proteinuria. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethics committee.
Because food intake may bias renal function, GFR was tested after an overnight fasting period in the supine position. CIn studies on urine and blood samples were conducted as described elsewhere, and results were adjusted to a standard body surface of 1.73 m 2 (12 ) . Serum creatinine was determined on the Dimension TM clinical chemistry system (Dade Behring) with a commercial assay based on the Jaffe method. The detection limit was 4 mol/L, defined as the concentration 2 SD above the CHEM I calibrator (Dade Behring) at 0 mol/L creatinine (n ϭ 20). The intraassay CV was 1% (mean, 61 mol/L; n ϭ 20), and the interassay CV was 2.5% (79.4 mol/L; n ϭ 20).
Serum cystatin C was analyzed by a fully automated latex-enhanced immunonephelometric method (N Latex Cystatin C Nephelometer II; Dade Behring). The detection limit of the assay was 0.05 mg/L with an intraassay CV of 1.9% (mean, 0.6 mg/L; n ϭ 20), and an interassay CV of 3.6% (mean, 0.6 mg/L; n ϭ 20). Reference intervals established from a population of 100 healthy male (median age, 35.5 years; 5th to 95th percentile, 20 -60 years) and 100 healthy female (median age, 27 years; 5th to 95th percentiles, 19 -55 years) blood donors were 0.5-0.82 mg/L (2.5th to 97.5th percentiles) for males and 0.5-0.74 mg/L for females; for creatinine, the reference intervals were 71-115 mol/L for males and 53-88.4 mol/L for females.
Statistical analysis was performed using Statview 4.5 for Macintosh (Abacus Concepts) and MedCalc for Windows (Mariakerke). Predictive performance was analyzed according to the method of Sheiner and Beal (10 ) ). The decrease appeared to be less pronounced in Child A cirrhosis, although the difference was not statistically significant (Table 1) . Patients with Child C and B cirrhosis had slightly higher values than patients with Child A cirrhosis (P ϭ 0.1, Kruskal-Wallis test). Cystatin C was significantly higher in patients with Child B and C cirrhosis than in those with Child A cirrhosis (Table 1) , whereas no differences were noted between patients with Child B and C cirrhosis.
The reciprocals of the creatinine and cystatin C concentrations (1/creatinine and 1/cystatin C) correlated significantly: 1/cystatin C (L/mg) ϭ 0.37 ϩ 45.47[1/creatinine (L/mol)]; r ϭ 0.662 (95% confidence interval, 0.458 -0.801); z-statistic, 5.1; P Ͻ0.0001. However, only 1/cystatin C (Fig. 1A) , but not 1/serum creatinine, was significantly correlated with the GFR (Fig. 1B) . The comparison of correlation coefficients revealed a significant difference between the two analytes in favor of 1/cystatin C (P ϭ 0.021; z-statistic ϭ Ϫ2.30).
To test the ability (10 ) of each analyte to predict GFR, we derived the following equations: GFR cystatin C (mL ⅐ min Ϫ1 ⅐ 1.73 m ; not significant) than that of 1/creatinine.
When we used a GFR of 90 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 as cutoff, 42 patients had an impaired GFR. Cystatin C showed a significantly higher sensitivity for detecting a reduced GFR than did creatinine (85.7% vs 28.5%; P ϭ 0.045, McNemar test).
Because many patients with cirrhosis and ascites have a reduced GFR but normal serum creatinine, alternative and reliable markers of GFR are needed (13) (14) (15) . Our analysis of 44 patients with liver cirrhosis demonstrates a significantly better correlation with the GFR for 1/cystatin C than for 1/creatinine. Most importantly, cystatin C shows a significantly higher sensitivity for detecting reduced GFR. Edema and ascites do not appear to influence the creatinine or cystatin C concentrations because control investigations showed similar concentrations of the analytes in serum and ascites (data not shown). Analysis of serum creatinine is an inexpensive and rapid tool to estimate GFR in daily practice. However, for the above-mentioned reasons, creatinine may overestimate GFR in cirrhotics (1, (3) (4) (5) . In fact, in our cohort, 25 of 38 patients (65.78%) with a GFR Ͻ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 exhibited normal creatinine values. CIn, which is widely regarded as the gold standard for determination of GFR, is impractical because of the necessity for steady-state infusion, a urine bladder catheter, and possible interference from blood glucose (1 ) . Although other plasma-clearance techniques, such as 99m Tc-diethylenetriaminepentaacetate have been used for estimation of GFR (16 -19 ) , it should be kept in mind that all plasmaclearance techniques become somewhat inaccurate when renal disease progresses to GFR values below 20 -30
Cystatin C is proposed to reflect GFR independent of age, height, and body composition (21) (22) (23) (24) . Recently, Kos and co-workers (25, 26 ) described an increase in the relative amount of cystatin C in malignant diseases such as colorectal cancer or melanoma. However, it should be stressed that these studies were carried out without a reference technique for measuring GFR (27 ) and thus cannot provide definite evidence that nonrenal factors affect serum concentrations of cystatin C.
In our cohort, the correlation coefficients for the reciprocals of serum cystatin C with creatinine and GFR were in the range of previous studies (6, 7, 9, 28 -31 ) . Some investigators found that cystatin C provides both better analytical performance and improved sensitivity in detecting early renal function loss (6, 9, (31) (32) (33) , whereas other investigators did not (7, 28, 30 ) .
We found a significant diagnostic advantage in using cystatin C serum measurements to detect a reduced GFR in cirrhotics; this was true mainly for patients with Child B and C cirrhosis exhibiting advanced GFR impairment (Fig. 1) .
In Fig. 1 , several values, including some for 1/cystatin C, were far off from a close correlation with the GFR. The reason for this skewing in some patients is difficult to explain because the patients did not differ with respect to the degree of liver failure or special treatments. However, despite the fact that cystatin C correlated better with the GFR in general than did creatinine, a recent publication showed that both analytes exhibit similar CVs at low GFR values (34 ) .
In conclusion, our study shows that the sensitivity of serum cystatin C for detecting reduced GFR is higher than that of creatinine in patients with liver cirrhosis. Therefore, serum cystatin C measurements may be useful in these patients. However, neither serum cystatin C nor creatinine reliably allows the prediction of the exact GFR in these patients. 
biochemically is a glycoprotein, structurally is a tetramer of identical subunits (182 000 Da each), and functionally is a major human plasma panproteinase inhibitor (1 ) . Its gene (A2M) has been mapped to chromosome 12p12-13 (2 ) . Investigations into the pathogenesis of Alzheimer disease (AD) revealed that ␣ 2 M is associated with senile plaques (3 ), binds to A␤ peptide, the major component of ␤-amyloid (4 ); attenuates fibrillogenesis and neurotoxicity of A␤ (4, 5 ) ; and mediates A␤ degradation (6, 7 ) . Activated ␣ 2 M, apolipoprotein E-enriched lipoproteins, and amyloid precursor protein share the same neuronal cell surface receptor, LDL receptor-related protein (␣ 2 M-r/LRP) (3, 7 ) . Consequently, there has been a growing interest in exploring possible associations between alterations of the A2M gene and AD risk. Two A2M polymorphisms, both involving functional domains, have been suggested to be related to AD risk (8 -11 ) . One involves a pentanucleotide deletion adjacent to a consensus splice site in intron 17 (5Ј to exon 18) of A2M, and it may cause exon skipping (12 ) . The other involves an A-to-G transition in exon 24, at position 1000 based on the cDNA sequence (13, 14 ) or at position 976 based on the mature protein (9 ) , and it changes Ile (ATC) to Val (GTC) near the thiol ester site of ␣ 2 M (9 ). The resulting polymorphism is of high frequency, with an allele distribution of 65-70% A and 30 -35% G in Caucasian populations (13) (14) (15) .
Current evidence for an A2M gene-AD risk connection is, however, conflicting. Several studies have failed to establish an association between AD and the pentanucleotide deletion near exon 18 (11, 16 -21 ) and/or the G allele of exon 24 (15, 21 ) of the A2M gene, and one study found that the A allele instead of the initially proposed G allele was a risk factor (11 ) . On the other hand, because ␣ 2 M is a major pan-proteinase inhibitor (1 ), it has been suggested that, similar to ␣ 1 -antitrypsin deficiency, defects in the A2M gene might also be involved in the pathogenesis of pulmonary disease (14 ) . For disease associations of A2M gene alterations, large populations need to be studied with practicable genotyping methods. With its robustness and effectiveness in detecting mutation, single-strand conformation polymorphism (SSCP) is such a method. For Clinical Chemistry 46, No. 5, 2000 
